PharmaCyte Biotech, Inc.
PMCBNASDAQHealthcare● Active
$0.70
+$0.00(+0.00%)
Market Cap$4757046
P/E Ratio—
52W High$1.51
52W Low$0.63
PharmaCyte Biotech, Inc. (PMCB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PMCB · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-04 | 2024-04 | 2023-04 | 2022-04 | 2021-04 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Operating Income | ($0.00B) | ($0.01B) | ($0.01B) | ($0.00B) | ($0.00B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.03B | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.03B | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-2.46 |
| Wtd Avg Shares | 0.01B | 0.01B | 0.02B | 0.02B | 0.00B |
| EBITDA | $0.03B | $0.01B | ($0.00B) | ($0.00B) | ($0.00B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more PharmaCyte Biotech, Inc. data
About PharmaCyte Biotech, Inc. (PMCB) Income Statement
PharmaCyte Biotech, Inc. (PMCB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PMCB reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of $0.03B — a net profit margin of —.
Frequently asked questions
PMCB · 4 questionsPharmaCyte Biotech, Inc. (PMCB) reported revenue of $0.00B for 2025, down —% year-over-year.
PMCB revenuePMCB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08